Jonathan Hahn - Kamada Director

KMDA Stock  ILA 1,937  49.00  2.47%   

Director

Mr. Jonathan Hahn is Director of the company. He has served on our board of directors since March 2010. Mr. Hahn is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York since 2010.
Age 32
Tenure 14 years
Professional MarksMBA
Phone(972) 8 9406472
Webwww.kamada.com
Hahn holds a BA degree from San Andrés University and an MBA degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.

Kamada Management Efficiency

Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 17.41 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 6.72, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kamada until it has trouble settling it off, either with new capital or with free cash flow. So, Kamada's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kamada sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kamada to invest in growth at high rates of return. When we think about Kamada's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Nurit SegalBank Leumi Le Israel
72
Sagi KablaTower Semiconductor
38
Avraham GuzmanTower Semiconductor
79
Amikam ShorerBezeq Israeli Telecommunication
49
Avraham DotanEl Al Israel
64
Amnon LipkinShahakEl Al Israel
68
Avraham BigerEl Al Israel
71
Eliyahu DefesEl Al Israel
61
Dov NinvehElbit Systems
71
Yigal NeemanElbit Systems
73
Mordechai KeretBezeq Israeli Telecommunication
60
David GranotBezeq Israeli Telecommunication
71
Yoav NardiBank Leumi Le Israel
72
Moshe DovratBank Leumi Le Israel
69
Shai HermeshBank Leumi Le Israel
70
Ohad MaraniBank Leumi Le Israel
63
Haggai HermanBezeq Israeli Telecommunication
51
Avraham AsheriElbit Systems
77
Yoram GabbayBank Leumi Le Israel
70
Dana GrossTower Semiconductor
51
Ester LevanonBank Leumi Le Israel
71
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 408 people. Kamada (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 355 people.

Management Performance

Kamada Leadership Team

Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pnina Strauss, Vice President - Inhalation programs & IP
Itzhak Krinsky, Director
Lilach Topilsky, Chairman of the Board
Ari Shamiss, Director
Barak Bashari, Vice President - Operations
Eran Schenker, Vice President - Medical Director
Tuvia Shoham, Independent Director
Eran Nir, Chief Officer
Hanni Neheman, VP Sales
Michal Stein, Vice President and Medical Director for Immunology
Ariella Raban, VP HR
Shani Dotan, Vice President of Human Resources
Liliana Bar, VP of RandD
Yael Brenner, Vice President - Quality
Abraham Havron, Independent Director
Asaf Frumerman, Director
Ruth Wolfson, Senior Vice President - Scientific Affairs
Shmuel Rubinstein, Director
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases
Jon Knight, VP Operations
Michael Berelowitz, Director
David Tsur, Co-Founder and Deputy Executive Chairman
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
Leon Recanati, Chairman of the Board
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO
Jonathan Hahn, Director
Eran Schenkar, Vice President - Medical Director
Gwen Melincoff, Director
Chaime Orlev, Chief Financial Officer
Michal Ayalon, Vice President - Research & Development
Yifat Esq, Gen Legal
Amir London, Chief Executive Officer
Estery GilozRan, Independent Director
Reuven Behar, Director
Eitan Kyiet, Vice President - Business Development
Ziv Kop, Director

Kamada Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Kamada Stock analysis

When running Kamada's price analysis, check to measure Kamada's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kamada is operating at the current time. Most of Kamada's value examination focuses on studying past and present price action to predict the probability of Kamada's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kamada's price. Additionally, you may evaluate how the addition of Kamada to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.